Objective
to report the results of the DynamX bioadaptor implant through 2years compared with the Resolute Onyx contemporary DES
Study
multicentre, single-blind, randomised controlled non-inferiority trial
Population
patients with de novo coronary lesions in up to 2 vessels
Endpoints
target lesion failure, which included cardiac death, target-vessel myocardial infarction, or clinically indicated target-lesion revascularisation
Conclusion
In patients with de novo coronary artery lesions, at two years the patients in the bioadaptor group exhibited fewer target lesion failures than the DES group.
Saito et al. JACC Cardiovasc Interv. 2025:S1936-8798(25)00497-2.